For Media Inquiries, Please Contact:
Jordan Berman
Global Director,
Corporate Communications
Apotex Inc.
4100
Weston Road,
North York,
ON, M9L 1P9
Canada
416-401-7487
Email
Press Center
-
Jun 12, 2017Apobiologix, a division of the Apotex Group focused on biologics innovation, today announced their support of the Supreme Court decision in the Sandoz v Amgen case. The case clarifies the timing of the Biologics Price Competition and Innovation Act (BPCIA) requiring biosimilar companies to provide 180-days notice to the companies of the reference products of intent to market the biosimilar.
-
Jun 8, 2017Two Toronto scientists who spearheaded the research that brought a life-saving drug to patients around the world are being honored at the annual Cooley's Anemia Foundation Gala tonight in New York City.
-
Apr 28, 2017The University of Saskatchewan and Apotex Inc. have renewed their partnership with a $1.6 million donation by the company to the College of Pharmacy and Nutrition.
-
Mar 8, 2017Today Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan
-
Mar 31, 2016Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada.
-
Mar 24, 2016Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.